Additionally, SGLT2 inhibitors have been shown to be beneficial in the prevention of AKI in two different randomized, placebo-controlled trials: Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) and Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) (137, 138). This evidence concerns the gene SLC5A2 and diabetes mellitus.